CUTANEOUS T-CELL LYMPHOMA WITH LYMPH NODE METASTASIS IN AN ADULT ADDAX (ADDAX NASOMACULATUS)

2017 ◽  
Vol 48 (3) ◽  
pp. 933-936 ◽  
Author(s):  
Zoltan S. Gyimesi ◽  
Roy B. Burns ◽  
Sheryl Coutermarsh-Ott ◽  
Chris A. Schiller ◽  
Rita McManamon
1992 ◽  
Vol 97 (1) ◽  
pp. 121-129 ◽  
Author(s):  
Eric C. Vonderheid ◽  
Lawrence W. Diamond ◽  
Sue-Min Lai ◽  
Francis Au ◽  
Michael A. Dellavecchia

2012 ◽  
Vol 2012 ◽  
pp. 1-4
Author(s):  
Jeffrey Carson ◽  
Jiri Bedrnicek ◽  
Shahab Abdessalam

We present a case of a 3-year-old male originally diagnosed with a CD30+ anaplastic cutaneous T-cell lymphoma with no evidence of systemic disease after CT scan, PET scan, and bone marrow aspiration. Sentinel lymph node biopsy (SLNB) was performed as an additional step in the workup and showed microscopic disease. Current management/recommendations for cutaneous T-cell lymphoma do not include SLNB. Medical and surgical management of cutaneous malignancies is dramatically different for local versus advanced disease. Therefore adequate evaluation is necessary to properly stage patients for specific treatment. Such distinction in extent of disease suggests more extensive therapy including locoregional radiation and systemic chemotherapy versus local excision only. Two international case reports have described SLNB in cutaneous T-cell lymphoma with one demonstrating evidence of node positive microscopic disease despite a negative metastatic disease workup. This case is being presented as a novel case in a child with implications including lymphoscintigraphy and SLNB as a routine procedure for evaluation and staging of cutaneous T-cell lymphoma if the patient does not demonstrate evidence of metastatic disease on routine workup.


Blood ◽  
2001 ◽  
Vol 97 (3) ◽  
pp. 624-630 ◽  
Author(s):  
Julia J. Scarisbrick ◽  
Sean Whittaker ◽  
Alun V. Evans ◽  
Elisabeth A. Fraser-Andrews ◽  
Fiona J. Child ◽  
...  

Abstract Erythrodermic cutaneous T-cell lymphoma (CTCL) includes patients with erythrodermic mycosis fungoides who may or may not exhibit blood involvement and Sézary syndrome and in whom hematological involvement is, by definition, present at diagnosis. These patients were stratified into 5 hematologic stages (H0-H4) by measuring blood tumor burden, and these data were correlated with survival. The study identified 57 patients: 3 had no evidence of hematologic involvement (H0), 8 had a peripheral blood T-cell clone detected by polymerase chain reaction (PCR) analysis of the T-cell receptor gene and less than 5% Sézary cells on peripheral blood smear (H1), and 14 had either a T-cell clone detected by Southern blot analysis or PCR positivity with more than 5% circulating Sézary cells (H2). Twenty-four patients had absolute Sézary counts of more than 1 × 109 cells per liter (H3), and 8 patients had counts in excess of 10 × 109 cells per liter (H4). The disease-specific death rate was higher with increasing hematologic stage, after correcting for age at diagnosis. A univariate analysis of 30 patients with defined lymph node stage found hematologic stage (P = .045) and lymph node stage (P = .013) but not age (P = .136) to be poor prognostic indicators of survival. Multivariate analysis identified only lymph node stage to be prognostically important, although likelihood ratio tests indicated that hematologic stage provides additional information (P = .035). Increasing tumor burden in blood and lymph nodes of patients with erythrodermic CTCL was associated with a worse prognosis.The data imply that a hematologic staging system could complement existing tumor-node-metastasis staging criteria in erythrodermic CTCL.


2016 ◽  
Vol 175 (6) ◽  
pp. 1397-1400 ◽  
Author(s):  
M. Battistella ◽  
C. Sallé de Chou ◽  
C. de Bazelaire ◽  
J.M. Cayuela ◽  
E. de Kerviler ◽  
...  

1988 ◽  
Vol 90 (4) ◽  
pp. 425-429 ◽  
Author(s):  
Stuart R. Lessin ◽  
Gary L. Grove ◽  
Lawrence W. Diamond ◽  
Francis C. Au ◽  
Peter C. Nowell ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document